Results 141 to 150 of about 7,754 (200)

Cost-effectiveness of antihistaminics in adults' patients with allergic rhinitis. [PDF]

Cost Eff Resour Alloc
Buendía JA, Patino DG.
europepmc   +1 more source

Acupuncture for nummular eczema of the lower legs in an older adult: a case report. [PDF]

Front Med (Lausanne)
Pan J, Yu H, Ye W, Liang Y.
europepmc   +1 more source

Advancements and challenges in the management of chronic inducible urticaria. [PDF]

Front Immunol
Zhang M, Liu J, Zhi Y.
europepmc   +1 more source

Substitutive Approach Toward Heteroaromatic Amino Alcohols Accessed Through Dioxolanyl Radical Linchpin. [PDF]

Adv Synth Catal
Chang JJ, Kumar M, Kashatus RC, Tomaselli DJ, Kim DK.   +4 more
europepmc   +1 more source

Omalizumab Combined with Cyclosporine for the Treatment and Management of Refractory Urticarial Vasculitis. [PDF]

Clin Cosmet Investig Dermatol
Chen X, Yu Q, Chang D, Sun L.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Desloratadine

Drugs, 2001
Desloratadine is the orally active major metabolite of the nonsedating H1-antihistamine loratadine. The drug had no adverse cardiovascular effects in various animal models or when administered at 9 times the recommended adult dosage for 10 days in volunteers.
Blair Jarvis
exaly   +5 more sources

Desloratadine for allergic rhinitis

Expert Review of Clinical Immunology, 2006
Seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) affect up to 40% of the population (depending on geographical area), and are associated with significant morbidity, socioeconomic costs and reductions in quality of life. Antihistamines are a first-line therapy, with newer nonsedating agents having superseded sedating first ...
Wilken, Jeffrey A., Daly, Adrian, Sullivan, Cynthia L., Kim, Harold   +3 more
openaire   +3 more sources

The Pharmacologic Profile of Desloratadine: A Review

Allergy: European Journal of Allergy and Clinical Immunology, 2001
Desloratadine is a new agent for the treatment of diseases such as seasonal allergic rhinitis and chronic urticaria. The pharmacologic profile of desloratadine offers particular benefits in terms of histamine H1‐receptor binding potency and H1 selectivity. Desloratadine has a half‐life of 21–24 h, permitting once‐daily dosing.
B M Henz
exaly   +3 more sources

Safety of Desloratadine Syrup in Children

Current Medical Research and Opinion, 2004
Allergic rhinitis (AR) and acute urticaria are common childhood maladies. Typically, the firstline treatment options for both include non-sedating antihistamines. First-generation antihistamines, such as diphenhydramine and hydroxyzine, although useful, cause sedation.
Heribert Staudinger
exaly   +3 more sources